益肾化湿颗粒联合布美他尼治疗慢性肾小球肾炎的临床研究

目的 探讨益肾化湿颗粒联合布美他尼片治疗慢性肾小球肾炎的治疗效果。方法 选取2020年5月—2023年4月溧阳市人民医院收治的120例慢性肾小球肾炎患者，按照计算机随机排列法将所有患者分为对照组（60例）和治疗组（60例）。对照组口服布美他尼片，2片/次，3次/d。治疗组在对照组基础上温水冲服益肾化湿颗粒，1袋/次，3次/d。两组患者持续治疗3个月。观察两组患者的临床疗效，比较两组的症状改善情况、肾功能和血清指标。结果 治疗组的总有效率（91.67%）明显高于对照组（78.33%），组间差异显著（P<0.05）。治疗后，治疗组患者水肿、血尿、蛋白尿消失时间均比对照组短（P<0.05）。治疗后，两组的肾小球滤过率（GFR）比治疗前大，肌酐（Scr）、胱抑素C(Cys-C)、尿蛋白排泄率（UAER）比治疗前小（P<0.05）；治疗组的GFR比对照组大，Scr、Cys-C、UAER比对照组小（P<0.05）。治疗后，两组的血清中性粒细胞明胶酶相关性载脂蛋白（NGAL）、单核细胞趋化蛋白-1(MCP-1)、白细胞诱素-1(Lkn-1)水平均比治疗前小（P<0.05...

Clinical study on Yishen Huashi Granules combined with bumetanide in treatment of chronic glomerulonephritis

Objective To explore the therapeutic effect of Yishen Huashi Granules and Bumetanide Tablets in treatment of chronic glomerulonephritis. Method Patients (120 cases) with chronic glomerulonephritis in Liyang People''s Hospital from May 2020 to April 2023 were divided into control and treatment groups according to the computer random arrangement method, and each group had 60 cases. Patients in the control group were po administered with Bumetanide Tablets, 2 tablets/time, three times daily. Patients in the treatment group were po administered with Yishen Huashi Granules on the basis of the control group, 1 bag/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and the symptom improvement, renal function, and serum markers in two groups were compared. Results The total effective rate of the treatment group (91.67%) was significantly higher than 78.33% of the control group, with significant difference between groups (P < 0.05). After treatment, the disappearance time of edema, hematuria, and proteinuria in the treatment group was shorter than that in the control group (P < 0.05). After treatment, the levels of GFR in two groups were higher than before treatment, but the levels of Scr, Cys-C, and UAER were lower than before treatment (P < 0.05). The levels of GFR in the treatment group were higher than that in the control group, but the levels of Scr, Cys-C, and UAER in the treatment group were higher than those in the control group (P < 0.05). After treatment, the serum levels of NGAL, MCP-1, and Lkn-1 in two groups were lower than before treatment (P < 0.05), and the serum levels of NGAL, MCP-1, and Lkn-1 in the treatment group were lower than those in the control group (P < 0.05). Conclusion Yishen Huashi Granules and Bumetanide Tablets in treatment of chronic glomerulonephritis can improve the clinical efficacy of chronic glomerulonephritis, significantly reduce clinical symptoms, improve renal function, and reduce the damage of renal tissue inflammation.